GlassScriptPhysician profile
Eugene V De Guzman
NPI 1699940874
$299.03
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2022: $92.34 · 2023: $3.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $100.15 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $92.94 | 2019 | |
| Opko Pharmaceuticals, LLC | $51.76 | 2019 | |
| Vifor Pharma, INC. | $26.12 | 2019-2022 | |
| Daiichi Sankyo INC. | $24.98 | 2019 | |
| Travere Therapeutics, INC. | $3.08 | 2023 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene De Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.